摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

maytansine | 35846-53-8

中文名称
——
中文别名
——
英文名称
maytansine
英文别名
[(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[acetyl(methyl)amino]propanoate
maytansine化学式
CAS
35846-53-8;70774-04-8;112244-10-7;112317-31-4
化学式
C34H46ClN3O10
mdl
——
分子量
692.206
InChiKey
WKPWGQKGSOKKOO-MFWPAQGOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    183.5-184℃
  • 比旋光度:
    D26 -145° (c = 0.055 in chloroform)
  • 沸点:
    895.1±65.0 °C(Predicted)
  • 密度:
    1.1049 (rough estimate)
  • 溶解度:
    DMF:1 mg/ml; DMSO:10 mg/ml;乙醇:2 mg/ml; PBS (pH 7.2):不溶

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    48
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    157
  • 氢给体数:
    2
  • 氢受体数:
    10

SDS

SDS:144b78f90b5116574e0d343a641cf150
查看

文献信息

  • [EN] PREPARATION OF MAYTANSINOID ESTERS<br/>[FR] PRÉPARATION D'ESTERS DE MAYTANSINOÏDE
    申请人:BIO THERA SOLUTIONS LTD
    公开号:WO2014094354A1
    公开(公告)日:2014-06-26
    Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.
    提供了一种高效的方法,用稀土金属基或三氟甲磺酸盐基的路易斯酸催化剂和碱以及偶联试剂直接偶联马坦西酮与羧酸,以高收率制备马坦西酮C-3酯。还提供了在这种方法中使用的组合物。
  • PREPARATION OF MAYTANSINOID ESTERS
    申请人:BIO-THERA SOLUTIONS, LTD., CO.
    公开号:US20140179917A1
    公开(公告)日:2014-06-26
    Provided are efficient methods for direct coupling of a maytansinoid with a carboxylic acid to prepare a maytansinoid C-3 ester in high yield using a rare earth metal-based or trifluoromethanesulfonate-based Lewis acid catalyst and a base together with a coupling reagent. Also provided are compositions used in such methods.
    提供了一种高效的方法,用于将马坦西酮与羧酸直接偶联,以制备高产率的马坦西酮C-3酯,使用基于稀土金属或三氟甲磺酸盐的路易斯酸催化剂和碱以及偶联试剂。还提供了在这种方法中使用的组合物。
  • MAYTANSINOID DERIVATIVES
    申请人:BIO-THERA SOLUTIONS, LTD., CO.
    公开号:US20140178414A1
    公开(公告)日:2014-06-26
    Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.
    本文披露了可能与抗原结合单元(Abu)结合的马替诺伊德药物连接物衍生物,以及与抗原结合单元结合的马替诺伊德药物(药物-连接物-抗原结合单元:D-L-Abu),用于靶向输送至疾病组织。提供了用于治疗癌症和免疫性疾病中的抗原阳性细胞的这种药物结合物的D-L-Abu、D-L-Abu衍生物和相关方法。
  • [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS PERMETTANT LE TRAITEMENT DE PATHOLOGIES ERB B2/NEU POSITIVES
    申请人:BIO THERA SOLUTIONS LTD
    公开号:WO2014094527A1
    公开(公告)日:2014-06-26
    Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.
    本文披露了与马替南素类药物结合的抗ERB B2/NEU抗体,用于靶向传递至疾病组织。提供了关于准备和使用这种药物结合物来治疗癌症中的ERB B2/NEU阳性细胞的方法。
  • [EN] MAYTANSINOID DERIVATIVES<br/>[FR] DÉRIVÉS DE MAYTANSINOÏDE
    申请人:BIO THERA SOLUTIONS LTD
    公开号:WO2014094353A1
    公开(公告)日:2014-06-26
    Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug- Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L- Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.
    本文披露了可能与抗原结合单元(Abu)连接的美坦西洛伊德药物连接物,以及与抗原结合单元连接的美坦西洛伊德药物(药物-连接剂-抗原结合单元:D-L-Abu),用于靶向传递至疾病组织。提供了D-L-Abu、D-L-Abu衍生物以及与利用这种药物共轭物治疗癌症和免疫性疾病中的抗原阳性细胞相关的方法。
查看更多